GAST and esophageal adenocarcinoma: A potential causal effect of gastrin on neoplastic progression in human Barrett’s esophagus (BE) has been supported by a study showing that serum gastrin levels were significantly correlated with cellular proliferation in nondysplastic BE patients on PPI therapy [8].